Form 4: Director Acquires NAMS Shares & Options

NewAmsterdam Pharma Co N.V. director Hilde Johanna van der Kamp acquired 3,400 restricted stock units and 15,300 stock options.

Summary

• Hilde Johanna van der Kamp, a Director of NewAmsterdam Pharma Co N.V. (NAMS), acquired 3,400 Restricted Stock Units (RSUs) and 15,300 stock options on January 7, 2026.
• The 3,400 RSUs represent a contingent right to receive one ordinary share each and will vest on January 7, 2027, subject to continued service through that date.
• The 15,300 stock options have an exercise price of $35.45 and will vest on January 2, 2027, also subject to continued service, with an expiration date of January 7, 2036.
• Both the RSUs and the stock options were granted for no consideration.
• Following these transactions, the director beneficially owns 10,360 ordinary shares (including RSUs) and 15,300 derivative options directly.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director is generally a positive signal, indicating confidence in the company's future. The long vesting periods further reinforce this long-term alignment of interests.

Positives

• A director acquiring additional equity (RSUs and options) can signal confidence in the company's future performance and long-term prospects.
• The vesting schedules for both RSUs and options, extending to 2027, align the director's long-term interests with shareholder value creation.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports an acquisition of equity by a director.

Future Outlook

The acquisition of long-term equity incentives, specifically RSUs and options with vesting periods extending to 2027 and options expiring in 2036, suggests an expectation of sustained value creation and continued service by the director, aligning their interests with the company's long-term success.

Industry Context

This filing is a routine insider transaction report, reflecting standard equity compensation practices for directors in publicly traded companies, particularly within the pharmaceutical sector. It does not provide broader industry-specific context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive, as the director's increased equity stake aligns their interests with long-term shareholder value creation and company performance.
• Employees: No direct impact on the broader employee base is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued service of Hilde Johanna van der Kamp through January 7, 2027, for the vesting of 3,400 RSUs.
• Continued service of Hilde Johanna van der Kamp through January 2, 2027, for the vesting of 15,300 stock options.

Key Dates

Recommendation

While the director's acquisition of equity is a positive signal of confidence in the company's future, a Form 4 filing alone typically does not provide sufficient comprehensive financial or strategic information to warrant a definitive 'buy' or 'sell' recommendation. It represents a routine insider transaction that aligns management interests with shareholders, supporting a 'hold' stance pending further fundamental analysis of the company's financial performance and strategic outlook.

Keywords

NewAmsterdam Pharma, NAMS, Form 4, Insider Trading, Director Stock Acquisition, Restricted Stock Units, Stock Options, Equity Compensation, Hilde Johanna van der Kamp